Patents Issued in June 18, 2020
  • Publication number: 20200188404
    Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.
    Type: Application
    Filed: November 6, 2017
    Publication date: June 18, 2020
    Inventors: Harold C. SMITH, Ryan P. BENNETT, Peter JAHRLING
  • Publication number: 20200188405
    Abstract: A method for treating choroidal neovascularization in a patient includes administrating as eye drops into the eye of the patient having choroidal neovascularization a therapeutically effective amount of an aqueous ophthalmic composition that is formulated for topical administration as eye drops. The aqueous ophthalmic composition consists essentially of Timolol Maleate at a concentration of about 0.1% to 0.5%, Dorzolamide at a concentration of about 0.5% to 2.5%, Prednisolone at a concentration of about 1.0% to 3.0%, Ketorolac Tromethamine at a concentration of about 0.4% to 1.2%, and sterile water at a concentration of at least about 90.0%.
    Type: Application
    Filed: February 25, 2020
    Publication date: June 18, 2020
    Inventor: Shalesh KAUSHAL
  • Publication number: 20200188406
    Abstract: The present invention relates to liquid formulations of Fosaprepitant intended for parenteral administration. Further the invention also describes process for preparing such formulations.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Leiutis Pharmaceuticals PVT. LTD.
    Inventors: Kocherlakota CHANDRASHEKHAR, Banda NAGARAJU
  • Publication number: 20200188407
    Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
    Type: Application
    Filed: November 15, 2019
    Publication date: June 18, 2020
    Inventors: Peter G. Schultz, Arnab K. Chatterjee, Shoutian Zhu, Joshua Payette, Hongchul Yoon, Baiyuan Yang
  • Publication number: 20200188408
    Abstract: An amorphous dispersion comprises bis(vinylcaprolactam) and an active pharmaceutical ingredient.
    Type: Application
    Filed: June 9, 2017
    Publication date: June 18, 2020
    Inventors: Osama M. MUSA, Jonathan W. STEED, David BERRY, Melissa J. GOODWIN
  • Publication number: 20200188409
    Abstract: There is described herein the use of mirtazapine in methods for the treatment of inflammatory disorders, autoimmune disease, and PBC.
    Type: Application
    Filed: September 7, 2018
    Publication date: June 18, 2020
    Inventors: Mark G. SWAIN, Abdel Aziz SHAHEEN, Wagdi ALMISHRI, Gilaad G. KAPLAN
  • Publication number: 20200188410
    Abstract: Provided herein are methods of treating cancer in an individual in need thereof, the methods comprising administering to the individual a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used. Also provided herein are methods of preventing precancerous cells expressing FRS2? from developing into cancer, the method comprising administering to an individual having precancerous cells expressing FRS2? a CXCR7 inhibitor. In some embodiments, additional therapeutic agents are used.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 18, 2020
    Inventors: Noriko GOTOH, James J. CAMPBELL
  • Publication number: 20200188411
    Abstract: Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: June 18, 2020
    Inventor: Nageswara R. Palepu
  • Publication number: 20200188412
    Abstract: The present invention relates to new compounds and compositions comprising active ingredient derivatives of testosterone, and novel testosterone derivatives, novel testosterone methods, novel testosterone compositions, novel testosterone articles of manufacture of pharmaceutical preparations and novel testosterone therapeutic uses thereof.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 18, 2020
    Inventors: Nathan Bryson, Avinash Chander Sharma
  • Publication number: 20200188413
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Application
    Filed: September 24, 2019
    Publication date: June 18, 2020
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Publication number: 20200188414
    Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.
    Type: Application
    Filed: November 7, 2019
    Publication date: June 18, 2020
    Inventors: Robert Emil Hodge, Jeffrey Douglas Webster
  • Publication number: 20200188415
    Abstract: Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs
  • Publication number: 20200188416
    Abstract: Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
    Type: Application
    Filed: February 11, 2020
    Publication date: June 18, 2020
    Inventors: Zijie Sun, David Horne, Junfeng Li, John E. Shively, Jun Xie
  • Publication number: 20200188417
    Abstract: Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.
    Type: Application
    Filed: May 29, 2018
    Publication date: June 18, 2020
    Applicant: RHOSHAN PHARMACEUTICALS, INC.
    Inventor: Nagesh R. PALEPU
  • Publication number: 20200188418
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Application
    Filed: February 27, 2020
    Publication date: June 18, 2020
    Inventors: Steven John TAYLOR, Mi-Jeong KIM, Kathleen NUDEL, Timothy F. BRIGGS, Koji YASUDA, Leonard BUCKBINDER, Bernard LANTER, Spencer Cory PECK, Cheri SNEDEKER, Angela SHE, Jessica ALEXANDER, Anna LIANG, Jenny LIU, Dinara GUNASEKERA, David Arthur BERRY, John Patrick CASEY, JR.
  • Publication number: 20200188419
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Publication number: 20200188420
    Abstract: The disclosure relates to compositions and methods for treating infection, allergic reactions, colitis, IBD, contact dermatitis, psoriasis, atopic dermatitis, graft vs. host disease and disorders and other disease and disorders comprising dendritic cell activation as well as compositions and method to improve allergen sensitization.
    Type: Application
    Filed: December 3, 2019
    Publication date: June 18, 2020
    Inventors: Richard L. Gallo, Tatsuya Dokoshi
  • Publication number: 20200188421
    Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of over-weight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to vitamin B12 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the off-spring, wherein the vitamin B12 is administered to an overweight and/or obese women desiring to get pregnant and/or to the over -weight and/or obese mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.
    Type: Application
    Filed: November 12, 2019
    Publication date: June 18, 2020
    Inventors: Cyrus Cooper, Peter David Gluckman, Irma Silva Zolezzi, Keith Malcolm Godfrey, Catherine Mace
  • Publication number: 20200188422
    Abstract: This current invention provides methods and agents for preventing and treating autoimmune and lymphoproliferative disease by targeting pathogenic age-associated B cells as well as methods of detecting these pathogenic age-associated B cells as a method of diagnosing and predicting autoimmune disease and other lymphoproliferative and chronic inflammatory disorders. The current invention also provides targets for drug development and basic research for autoimmune diseases and other lymphoproliferative and chronic inflammatory disorders.
    Type: Application
    Filed: July 26, 2019
    Publication date: June 18, 2020
    Inventors: Alessandra Pernis, Michela Manni
  • Publication number: 20200188423
    Abstract: The purpose of the present invention is to provide a therapeutic agent which is for inflammatory bowel disease and exhibits superior prophylactic or therapeutic effects on inflammatory bowel disease by using miR-29a and/or miR-29h. The prophylactic or therapeutic agent for inflammatory bowel disease comprises composite particles in which miR-29a and/or miR-29b is/are carried on carbonate apatite particles, and said agent is administered systemically.
    Type: Application
    Filed: April 24, 2018
    Publication date: June 18, 2020
    Inventors: Hirofumi YAMAMOTO, Masaki MORI
  • Publication number: 20200188424
    Abstract: A method of treating a disease associated with fibrosis is disclosed. The method comprises administering to the subject a therapeutically effective amount of exosomes isolated from a hepatic cell-conditioned medium. Administration of agents isolated from the exosomes for treatment of fibrotic diseases is also contemplated.
    Type: Application
    Filed: August 30, 2018
    Publication date: June 18, 2020
    Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Ziv BEN-ARI, Michal SAFRAN, Maya SULTAN
  • Publication number: 20200188425
    Abstract: This invention relates generally to compositions and methods for combating inflammatory disease and particularly to the use of food and/or feed compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts, wherein the compositions comprising at least one specific pectin.
    Type: Application
    Filed: November 26, 2019
    Publication date: June 18, 2020
    Inventors: Hendrik ARIE SCHOLS, Paulus DE VOS, Marco Alexander VAN DEN BERG, Geert BRUGGEMAN, Erik Martinus Andrianus Maria BRUININX, Neha Mohan SAHASRABUDHE, Jan SCHOLTE, Lingmin TIAN, Anton Johannes SCHEURINK
  • Publication number: 20200188426
    Abstract: A method for wound management in the prevention of bioburden and/or biofilm includes conducting an initial risk assessment protocol with regard to a wound, washing the wound and surrounding skin, applying a polyethylene carbonate composition on and around the wound, eradicating any organisms as methylene chloride of the polyethylene carbonate composition evaporates and polyethylene carbonate polymer of the polyethylene carbonate composition polymerizes, and allowing time for formation of a clear elastomeric film barrier over the wound and around the wound.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 18, 2020
    Inventors: Julie Marie Morris, Jeffrey Steven Elbl
  • Publication number: 20200188427
    Abstract: The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.
    Type: Application
    Filed: August 30, 2018
    Publication date: June 18, 2020
    Inventors: Andreas Viktor SIMM, Jorg SCHEIER, Christian STEINER, Vincent CAPPONI, Phillip P. CHAN
  • Publication number: 20200188428
    Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.
    Type: Application
    Filed: September 13, 2018
    Publication date: June 18, 2020
    Applicant: Shenzhen Profound-View Pharma Tech Co., Ltd
    Inventor: Taolei SUN
  • Publication number: 20200188429
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals. The invention further includes pharmaceutical compositions thereof and the use of the gold nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which gold therapy is already known and more generally for conditions resulting from pathological cellular activation, such as inflammatory (including chronic inflammatory) conditions, autoimmune conditions, hypersensitivity reactions and/or cancerous diseases or conditions.
    Type: Application
    Filed: August 8, 2019
    Publication date: June 18, 2020
    Applicant: Clene Nanomedicine, Inc.
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Publication number: 20200188430
    Abstract: Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Oregon State University
    Inventors: Joseph Beckman, James Hurst, John Sirois, Chris Beaudry
  • Publication number: 20200188431
    Abstract: The present invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle wasting occurs. The invention provides the use of inhibitors of glutamine dehydrogenase for the regeneration of skeletal muscle.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 18, 2020
    Inventors: Massimiliano Mazzone, Min Shang
  • Publication number: 20200188432
    Abstract: Methods for treating AL amyloidosis using chimeric antigen receptors targeting CS1 are described.
    Type: Application
    Filed: March 20, 2018
    Publication date: June 18, 2020
    Inventors: Xiuli Wang, Stephen J. Forman
  • Publication number: 20200188433
    Abstract: Contemplated treatment compositions and methods are directed to co-administration of sensitized genetically modified NK cells and recombinant IL-12, wherein the genetically modified NK cells were preferably sensitized by constitutive exposure to IL-2 and wherein the IL-12 is expressed from a recombinant virus or given as an IL-12-antibody conjugate. Such treatment increases IFN? secretion by the sensitized NK cells, and advantageously also increases expression of NKG2D.
    Type: Application
    Filed: March 26, 2018
    Publication date: June 18, 2020
    Inventors: Patrick SOON-SHIONG, Kayvan NIAZI
  • Publication number: 20200188434
    Abstract: The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) which comprises an antigen binding domain and an intracellular signalling domain; (ii) a membrane tethering component (MTC) which comprises a first dimerization domain; and (Hi) a signal-dampening component (SDC) comprising a signal-dampening domain (SDD) and a second dimerization domain which specifically binds the first dimerisation domain of the membrane-tethering component. Dimerisation between the MTC and SDC may be controllable with an agent, meaning that the agent can be used to control CAR-mediated cell signalling.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 18, 2020
    Inventors: Shaun Cordoba, Evangelia Kokalaki, Martin Pulé, Simon Thomas, Shimobi Onuoha
  • Publication number: 20200188435
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 18, 2020
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU
  • Publication number: 20200188436
    Abstract: The present invention provides compositions and methods for combination therapy comprising administering to a patient in need thereof, drug-resistant immunotherapy, immune checkpoint inhibitors, and chemotherapy for the treatment of cancer.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: William Ho, JR., Lawrence S. Lamb, JR.
  • Publication number: 20200188437
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7×106 cells/mL or more, and of the about 7×106 cells/mL, about 90% or more are CD8+ T cells.
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Inventors: Byoung S. Kwon, Young Ho Kim, Mun Ki Kim, Kwang Hee Kim, You Hyun Kang
  • Publication number: 20200188438
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: December 17, 2019
    Publication date: June 18, 2020
    Inventors: Gisela SCHIMMACK, Annika SONNTAG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Michael ROEMER, Jens FRITSCHE, Oliver SCHOOR, Toni WEINSCHENK, Harpreet SINGH
  • Publication number: 20200188439
    Abstract: Methods of treating progressive forms of multiple sclerosis are provided, comprising administering adipose-derived stem cells into the central nervous system (CNS). Further provided are improved methods for obtaining ADSCs, which are more cost effective and which provide higher yields compared to currently used methods.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 18, 2020
    Applicant: STEM CELL MEDICINE LTD.
    Inventors: Ehud MAROM, Frida GRYNSPAN, Dima YUDIN
  • Publication number: 20200188440
    Abstract: Methods of treating an aging-associated disease, as well as inhibiting aging in a subject, by administering pharmaceutical compositions comprising unmodified and modified MSCs and their exosomes are provided.
    Type: Application
    Filed: May 16, 2018
    Publication date: June 18, 2020
    Inventors: Chaya BRODIE, Aharon BRODIE
  • Publication number: 20200188441
    Abstract: Provided herein are, inter alia, methods and compositions for reducing and/or preventing ocular endothelial cell loss, and for treatment and/or prevention of ocular diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 18, 2020
    Inventors: Reza Dana, Ahmad Kheirkhah, Ula V. Jurkunas
  • Publication number: 20200188442
    Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes or a sterile fecal filtrate for treating Parkinson's disease and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
    Type: Application
    Filed: April 4, 2018
    Publication date: June 18, 2020
    Applicant: Crestovo Holdings LLC
    Inventor: Thomas J. Borody
  • Publication number: 20200188443
    Abstract: A method for obtaining epithelial organoids is provided. In one embodiment, the method comprises culturing one or more epithelial ducts, epithelial duct fragments and/or epithelial stem cells isolated therefrom in contact with an extracellular matrix in the presence of a basal medium, wherein the medium is free of FGF and/or nicotinamide. Organoids obtained by the methods described herein, and uses thereof, are also provided.
    Type: Application
    Filed: May 29, 2018
    Publication date: June 18, 2020
    Inventors: Charis-Patricia Segeritz, Ryan Conder, Michael Riedel
  • Publication number: 20200188444
    Abstract: The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic stellate progenitor cells. The present invention also pertains to a pharmaceutical composition or kit comprising the above-mentioned cells, a liver cellular tissue model, or a cell fraction.
    Type: Application
    Filed: November 15, 2019
    Publication date: June 18, 2020
    Applicant: The University of Tokyo
    Inventors: Atsushi Miyajima, Taketomo Kido, Yuta Koui, Ayaka Kobayashi
  • Publication number: 20200188445
    Abstract: A method includes covering or contacting a portion of a parathyroid of a subject with a shield including extraembryonic tissue and/or a parathyroid protective injection. The covering occurs during a neck or reconstructive surgery of the subject.
    Type: Application
    Filed: May 29, 2019
    Publication date: June 18, 2020
    Inventor: James Glenn Norman
  • Publication number: 20200188446
    Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.
    Type: Application
    Filed: February 24, 2020
    Publication date: June 18, 2020
    Applicant: CELULARITY, INC.
    Inventor: Robert J. Hariri
  • Publication number: 20200188447
    Abstract: A cosmetic or dermatological preparation that contains an aqueous and a lipophilic fish egg extract for replumping skin; for increasing the incorporation of triglycerides in adipocytes; for increasing the expression of laminin, preferably of laminin-5 and most preferably of laminin-5 ? sub-unit; and/or for maintaining the skin elasticity and/or resilience of human skin.
    Type: Application
    Filed: May 11, 2018
    Publication date: June 18, 2020
    Inventors: Daniel STANGL, Bernhard DUDLER
  • Publication number: 20200188448
    Abstract: The present invention relates to a coral composite extract, a composition including the same and a method of producing the same. The coral composite extract includes at least two briarane-type diterpenoid compounds from corals of Briareum violaceum, B. excavatum and B. stechei, thereby being applied as an effective ingredient of a skin external use composition, a cosmetic composition and a medicinal composition.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Inventors: Zhi-Hong Wen, Ping-Jyun Sung, Han-Chun Hung, Chun-Hong Chen, Yu-Chia Chang
  • Publication number: 20200188449
    Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating chronic fatigue syndrome and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
    Type: Application
    Filed: October 11, 2017
    Publication date: June 18, 2020
    Applicant: Crestovo Holdings LLC
    Inventor: Thomas Julius BORODY
  • Publication number: 20200188450
    Abstract: The invention relates to a fecal microbiota sample for use in the prevention and/or treatment of infectious or non-infectious complications resulting from allogeneic hematopoietic stem cell (HSC) transplantation, or for the treatment of cancer in a recipient patient, said fecal microbiota sample and said hematopoietic stem cells originating from the same donor subject, or said fecal microbiota sample being administered prior to HSC transplantation.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 18, 2020
    Inventors: Mohamad MOHTY, Harry SOKOL
  • Publication number: 20200188451
    Abstract: Provided herein are compositions comprising Oxalobacter formigenes (Of)-derived factors and variants and fragments thereof, and method of use thereof for the treatment/prevention excess oxalate levels and conditions and diseases related thereto.
    Type: Application
    Filed: January 19, 2018
    Publication date: June 18, 2020
    Inventors: Hatim A. Hassan, Donna Arvans
  • Publication number: 20200188452
    Abstract: Compositions and methods for treating or reducing the severity of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a composition comprising isolated native, bioactive nematicidal crystals formed from a single type of nematicidal crystal protein. The isolated native, bioactive nematicidal crystals are substantially free of any bacterial spores or host bacterial proteins, other than nematicidal crystal protein in the form of a crystal. Methods for making isolated native, bioactive nematicidal crystals are also described. The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A.
    Type: Application
    Filed: May 22, 2018
    Publication date: June 18, 2020
    Inventors: Raffi Van Aroian, Gary R. Ostroff
  • Publication number: 20200188453
    Abstract: The invention provides a method which comprises administering an effective amount of a probiotic composition including Lactobacillus plantarum TWK10 for improving inflammation after exercise. The Lactobacillus plantarum TWK10 is deposited in Taiwan Food Industry Research and Development Institute (FIRDI) with the accession number BCRC910734, and in China General Microbiological Culture Collection Center (CGMCC) with the accession number CGMCC 13008.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 18, 2020
    Inventors: Chi-Chang Huang, Wen-Ching Huang, Jin-Sheng Lin, Mon-Chien Lee, Ker-Sin Ng